German Drug Firms Slam Healthcare Reforms

German pharmaceutical companies have strongly criticised a Health Ministry working paper on the healthcare reform draft legislation which could lead to price caps for newly launched branded drugs. In what they see as a blow to innovation, domestic companies Schwarz Pharma and Schering AG said that the limitations of pricing will lead to less money to fund the research and development of new medicines.

To read the full article, please choose one of the following options: